Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination

Published:2020-03-24 Issue:1 Volume:52 Page:269-279
ISSN:1941-6628
Container-title:Journal of Gastrointestinal Cancer
language:en
Short-container-title:J Gastrointest Canc

Author:

El Shorbagy Shereen,abuTaleb Fouad,Labib Hany A.,Ebian Huda,Harb Ola A.,Mohammed Mona Saeed,Rashied Hanaa A.,Elbana Khaled A.,Haggag Rasha

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s12029-020-00389-w.pdf

Reference47 articles.

1. Hollebecque A, Malka D, Ferte C, et al. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur J Cancer. 2015;51:327–39.

2. Balogh J, Victor D, Asham EH, Gordon S, Boktour M. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;2016(3):41–53.

3. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel HA. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:437971.

4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma;Molecular Cancer;2024-09-06

2. Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma;Frontiers in Oncology;2024-06-27

3. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials;Clinical Pharmacology & Therapeutics;2024-05-27

4. A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update;International Journal of Molecular Sciences;2024-03-14

5. GSH-related enzyme activity and tumor relation: glutathione peroxidase and glutathione reductase status under hypoxia in HepG2 cells;Turkish Journal of Biochemistry;2024-03-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3